Benovus Bio’s scientific technology is based on immunologic approaches targeting the Oncofetal Antigen/immature Laminin Receptor Protein (OFA/iLRP), a well-conserved, cancer-specific antigen expressed on the cell surface of human cancer biopsies and in over 500 cancer lines tested to date.

Extensive research has demonstrated that the OFA/iLRP antigen is significantly over expressed on: 1) cancer cells, and 2) fetuses through the mid-gestational period. These features make the ubiquitous OFA/iLRP an optimal and previously unexploited target for Benovus Bio’s proprietary and patent protected monoclonal antibodies and immunogenic peptides. These characteristics also create the potential for developing active and passive specific immunotherapies for a wide array of cancers.